ci 988 has been researched along with phenylalanine in 10 studies
| Studies (ci 988) | Trials (ci 988) | Recent Studies (post-2010) (ci 988) | Studies (phenylalanine) | Trials (phenylalanine) | Recent Studies (post-2010) (phenylalanine) |
|---|---|---|---|---|---|
| 147 | 8 | 14 | 23,695 | 721 | 4,367 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (90.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blommaert, A; Fournié-Zaluski, MC; Noble, F; Roques, BP | 1 |
| Blommaert, AG; Ducos, B; Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O | 1 |
| Fournie-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O | 1 |
| Blommaert, AG; Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Valverde, O | 1 |
| Horwell, D; Pritchard, M; Raphy, J; Ratcliffe, G | 1 |
| Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Ruiz, F | 1 |
| Besson, JM; Buritova, J; Fournié-Zaluski, MC; Honore, P; Roques, BP | 1 |
| Elfvin, A; Fournié-Zaluski, MC; Hao, JX; Roques, BP; Wiesenfeld-Hallin, Z; Xu, XJ | 1 |
| Coric, P; Fournié-Zaluski, MC; Maldonado, R; Roques, BP; Ruiz, F; Smadja, C | 1 |
| Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP | 1 |
1 review(s) available for ci 988 and phenylalanine
| Article | Year |
|---|---|
'Targeted' molecular diversity: design and development of non-peptide antagonists for cholecystokinin and tachykinin receptors.
Topics: Amino Acid Sequence; Animals; Drug Design; Drug Evaluation, Preclinical; Hormone Antagonists; Humans; Indoles; Ligands; Meglumine; Molecular Structure; Oligopeptides; Peptide Library; Phenylalanine; Receptors, Cholecystokinin; Receptors, Tachykinin; Tryptophan | 1996 |
9 other study(ies) available for ci 988 and phenylalanine
| Article | Year |
|---|---|
A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
Topics: Analgesics; Animals; Disulfides; Enkephalins; Formaldehyde; Indoles; Male; Meglumine; Mice; Morphine; Naloxone; Naltrexone; Pain Measurement; Phenylalanine; Receptors, Cholecystokinin; Receptors, Opioid, delta; Receptors, Opioid, mu | 1995 |
Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
Topics: Analgesics; Animals; Behavior, Animal; Binding, Competitive; Body Temperature; Diprenorphine; Disulfides; Drug Combinations; Drug Synergism; Enkephalins; Indoles; Male; Meglumine; Mice; Morphine; Motor Activity; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome; Weight Loss | 1995 |
Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
Topics: Adamantane; Analgesics; Animals; Benzodiazepinones; Dipeptides; Disulfides; Drug Synergism; Enkephalins; Indoles; Male; Meglumine; Nociceptors; Pain Measurement; Phenylalanine; Phenylurea Compounds; Prodrugs; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Regression Analysis; Tail | 1994 |
Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
Topics: Analgesics; Animals; Benzodiazepinones; Disulfides; Drug Synergism; Drug Tolerance; Indoles; Male; Meglumine; Mice; Pain Measurement; Phenylalanine; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Time Factors | 1995 |
Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
Topics: Analgesics; Animals; Disulfides; Drug Combinations; Enkephalins; Indoles; Male; Meglumine; Methadone; Morphine; Naloxone; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Cholecystokinin; Substance Withdrawal Syndrome | 1996 |
Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
Topics: Analgesics; Animals; Benzodiazepinones; Devazepide; Disulfides; Dose-Response Relationship, Drug; Edema; Enzyme Inhibitors; Indoles; Male; Meglumine; Pain; Phenylalanine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Spinal Cord | 1997 |
CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
Topics: Analgesics; Animals; Decerebrate State; Disulfides; Dose-Response Relationship, Drug; Drug Synergism; Female; Hormone Antagonists; Indoles; Injections, Intravenous; Meglumine; Nociceptors; Opioid Peptides; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Reflex; Spinal Cord | 1997 |
CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
Topics: Amygdala; Animals; Caudate Nucleus; Disulfides; Enkephalins; Enzyme Inhibitors; Hormone Antagonists; Indoles; Injections, Intraventricular; Limbic System; Male; Meglumine; Mice; Motor Activity; Neprilysin; Nucleus Accumbens; Phenylalanine; Rats; Rats, Wistar; Receptor, Cholecystokinin B; Receptors, Cholecystokinin | 1997 |
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss | 2001 |